UA93517C2 - Amorphous solid dispersion formulations comprising 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide - Google Patents

Amorphous solid dispersion formulations comprising 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide

Info

Publication number
UA93517C2
UA93517C2 UAA200803944A UAA200803944A UA93517C2 UA 93517 C2 UA93517 C2 UA 93517C2 UA A200803944 A UAA200803944 A UA A200803944A UA A200803944 A UAA200803944 A UA A200803944A UA 93517 C2 UA93517 C2 UA 93517C2
Authority
UA
Ukraine
Prior art keywords
pyridazino
acetamide
indole
dihydro
trimethyl
Prior art date
Application number
UAA200803944A
Other languages
English (en)
Russian (ru)
Inventor
Ирвин K. Джейкобс
Джон Д. Хиггинс
Микаэл Гюилло
Нэнси M. Френсон
Уильям Л. Рокко
Хавла Абдулла Абу-Изза
Original Assignee
САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37499538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93517(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи filed Critical САНОФИ-АВЕНТИС Ю.Эс. ЭлЭлСи
Publication of UA93517C2 publication Critical patent/UA93517C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
UAA200803944A 2005-08-29 2006-08-24 Amorphous solid dispersion formulations comprising 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide UA93517C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71215005P 2005-08-29 2005-08-29

Publications (1)

Publication Number Publication Date
UA93517C2 true UA93517C2 (en) 2011-02-25

Family

ID=37499538

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200803944A UA93517C2 (en) 2005-08-29 2006-08-24 Amorphous solid dispersion formulations comprising 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4h-pyridazino[4,5-b]indole-1-acetamide

Country Status (30)

Country Link
US (1) US7713548B2 (enExample)
EP (1) EP1926476B1 (enExample)
JP (1) JP5026426B2 (enExample)
KR (1) KR20080061354A (enExample)
CN (1) CN101272767B (enExample)
AR (1) AR055615A1 (enExample)
AU (1) AU2006285111B8 (enExample)
BR (1) BRPI0615609A2 (enExample)
CA (1) CA2619438A1 (enExample)
CR (1) CR9750A (enExample)
DK (1) DK1926476T3 (enExample)
EA (1) EA015715B1 (enExample)
EC (1) ECSP088203A (enExample)
ES (1) ES2414434T3 (enExample)
HN (1) HN2008000360A (enExample)
HR (1) HRP20130533T1 (enExample)
IL (1) IL189587A (enExample)
MA (1) MA29783B1 (enExample)
ME (1) ME01560B (enExample)
NO (1) NO20081364L (enExample)
NZ (1) NZ566313A (enExample)
PL (1) PL1926476T3 (enExample)
PT (1) PT1926476E (enExample)
RS (1) RS52914B (enExample)
SI (1) SI1926476T1 (enExample)
TN (1) TNSN08069A1 (enExample)
TW (1) TWI398250B (enExample)
UA (1) UA93517C2 (enExample)
WO (1) WO2007027494A2 (enExample)
ZA (1) ZA200801893B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2674428T3 (pl) 2006-04-07 2017-01-31 Vertex Pharmaceuticals Incorporated Modulatory transporterów z kasetą wiążącą ATP
USRE50453E1 (en) 2006-04-07 2025-06-10 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
WO2008138755A2 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
CA2717326C (en) * 2008-03-11 2018-10-23 Dr. Reddy's Laboratories Ltd. Preparation of lenalidomide
EP2364315A1 (en) * 2008-08-18 2011-09-14 Sanofi-Aventis U.S. LLC Process for preparing polymorph of 7-chloro-n, n,5-trimethyl-4-oxo-3-phenyl-3,5-dihydr0-4h-pyridazin0[4,5-b]indole-1-acetamide
NZ700556A (en) * 2010-03-25 2016-04-29 Vertex Pharma Solid forms of (r)-1(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
US9801855B2 (en) 2012-03-07 2017-10-31 National Institute Of Pharmaceutical Education And Research (Niper) Nanocrystalline solid dispersion compositions and process of preparation thereof
KR101986683B1 (ko) 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
WO2015030788A1 (en) * 2013-08-30 2015-03-05 Hewlett-Packard Development Company, L.P. Comparing real-time movements to pattern profile background
CA2943024A1 (en) 2014-03-18 2015-09-24 Takeda Pharmaceutical Company Limited Solid dispersion
RS62140B1 (sr) 2014-04-15 2021-08-31 Vertex Pharma Farmaceutske kompozicije za lečenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
KR20200118507A (ko) 2016-02-29 2020-10-15 에프. 호프만-라 로슈 아게 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물
JP7190452B2 (ja) * 2017-07-04 2022-12-15 ジエンス ヘンルイ メデイシンカンパニー リミテッド 医薬組成物及びその製造方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5091381A (en) * 1991-04-12 1992-02-25 Biomeasure, Inc. 2H-1,3,4-benzotriazepin-2-ones
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
FR2766823B1 (fr) 1997-07-30 1999-10-08 Synthelabo Derives de 4-oxo-3,5-dihydro-4h-pyridazino[4,5-b] indole-1-acetamide, leur preparation et leur application en therapeutique
PT901786E (pt) * 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
AUPP278498A0 (en) * 1998-04-03 1998-04-30 Australian Nuclear Science & Technology Organisation Peripheral benzodiazepine receptor binding agents
FR2788696B1 (fr) * 1999-01-26 2004-03-05 Synthelabo Utilisation de derives de pyridazino [4,5-b] indole-1-acetamide pour la preparation de medicaments destines aux maladies du systeme nerveux central
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
EP1027887B1 (en) * 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
EP1120109A3 (en) * 2000-01-24 2002-07-10 Pfizer Products Inc. Rapidly disintegrating and fast dissolving solid dosage form
FR2829939B3 (fr) * 2001-09-21 2003-11-28 Sanofi Synthelabo Utilisation du 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5- dihydro-4h-pyridazino(4,5-b)indole-1-acetamide pour la preparation de medicaments destines au traitement de la polyarthrite rhumatoide
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050220881A1 (en) * 2003-10-10 2005-10-06 Bvm Holding Co. Pharmaceutical composition

Also Published As

Publication number Publication date
HRP20130533T1 (en) 2013-07-31
PL1926476T3 (pl) 2013-08-30
TW200727902A (en) 2007-08-01
MA29783B1 (fr) 2008-09-01
BRPI0615609A2 (pt) 2011-05-24
ME01560B (me) 2014-04-20
CA2619438A1 (en) 2007-03-08
AU2006285111A1 (en) 2007-03-08
ZA200801893B (en) 2009-08-26
HN2008000360A (es) 2011-05-31
SI1926476T1 (sl) 2013-07-31
KR20080061354A (ko) 2008-07-02
US20080160080A1 (en) 2008-07-03
EP1926476B1 (en) 2013-04-10
PT1926476E (pt) 2013-07-10
EA015715B1 (ru) 2011-10-31
RS52914B (sr) 2014-02-28
ES2414434T3 (es) 2013-07-19
HK1124785A1 (en) 2009-07-24
AR055615A1 (es) 2007-08-29
EA200800713A1 (ru) 2008-10-30
WO2007027494A2 (en) 2007-03-08
TNSN08069A1 (en) 2009-07-14
JP2009506114A (ja) 2009-02-12
IL189587A (en) 2012-12-31
CR9750A (es) 2008-06-18
ECSP088203A (es) 2008-06-30
TWI398250B (zh) 2013-06-11
NZ566313A (en) 2011-04-29
IL189587A0 (en) 2008-08-07
WO2007027494A3 (en) 2007-08-02
AU2006285111B2 (en) 2012-04-26
DK1926476T3 (da) 2013-07-01
NO20081364L (no) 2008-04-03
CN101272767B (zh) 2012-08-29
EP1926476A2 (en) 2008-06-04
AU2006285111B8 (en) 2012-05-17
JP5026426B2 (ja) 2012-09-12
US7713548B2 (en) 2010-05-11
CN101272767A (zh) 2008-09-24

Similar Documents

Publication Publication Date Title
TNSN08069A1 (en) Amorphous solid dispersions of 7-chloro-n,n,5-trimethyl-4-oxo-3-phenyl-3,5,-dihydro-4h-pyridazino[4,5 b] indole -1- acetamide
IL209494A (en) Formulations of insulin oligomeric monoconogues and their use
EP2223921B8 (en) 2-Thiophen-2-yl-oxazole, 2-Thiophen-2-yl-thiazole and 2-Thiophen-2-yl-1H-imidazole derivatives as antiviral agents
SG153834A1 (en) 1-aza-bicyclo[3.3.1]nonanes
WO2007011741A3 (en) Stable organic devices
WO2007076370A3 (en) Block copolymer particles
WO2007014373A3 (en) Novel cells, compositions, and methods
SG148192A1 (en) Azabenzimidazole derivatives, their manufacture and use as anti-cancer agents
GB0710111D0 (en) Pyrrolo [2, 1-C] [1, 4] benzodiazepine-anthraquinone conjugates useful as antitumour agents
IL188111A0 (en) 2,5-bis-diamimne [1,4] benzoquinone-derivatives
AU2011205115B2 (en) Insulin-oligomer conjugates, formulations and uses thereof
AU2005900833A0 (en) P.K.'s Quarterball
HK1122289A (en) Solid formulations
HK1113090A (en) Antibiotic formulations, unit doses, kits, and methods
HK1108387A (en) 3, 6-bicyclolides
AU2005900437A0 (en) An Improved Axle Arrangement
AU2005900030A0 (en) Glowbal, Glowves, Moonstik
AU2005905768A0 (en) Therapeutic methods, compositions and kits
AU2005903018A0 (en) Adjustable high chair
AU2004906102A0 (en) Softshu horseshoe Rev. I
AU2005906280A0 (en) Budgetchoice.com
AU2004900567A0 (en) Cashramspam, cashramsell, cashramfoto etc
AU306758S (en) Console
HK1116170A (zh) 吡啶並(3，2-d)嘧啶和藥物組合物用於治療丙肝
CY1114124T1 (el) Αμορφες στερεες διασπορες της 7-χλωρο-ν,ν,5-τριμεθυλ-4-οξο-3-φαινυλ-3,5- διϋδρο-4η-πυριδαζινο[4,5-β]ινδολη-1-ακεταμιδης